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Abstract
Background: Using array comparative genomic hybridization (aCGH), a large number of deleted
genomic regions have been identified in human cancers. However, subsequent efforts to identify
target genes selected for inactivation in these regions have often been challenging.
Methods: We integrated here genome-wide copy number data with gene expression data and
non-sense mediated mRNA decay rates in breast cancer cell lines to prioritize gene candidates that
are likely to be tumour suppressor genes inactivated by bi-allelic genetic events. The candidates
were sequenced to identify potential mutations.
Results: This integrated genomic approach led to the identification of RIC8A at 11p15 as a putative
candidate target gene for the genomic deletion in the ZR-75-1 breast cancer cell line. We identified
a truncating mutation in this cell line, leading to loss of expression and rapid decay of the transcript.
We screened 127 breast cancers for RIC8A mutations, but did not find any pathogenic mutations.
No promoter hypermethylation in these tumours was detected either. However, analysis of gene
expression data from breast tumours identified a small group of aggressive tumours that displayed
low levels of RIC8A transcripts. qRT-PCR analysis of 38 breast tumours showed a strong association
between low RIC8A expression and the presence of TP53 mutations (P = 0.006).
Conclusion: We demonstrate a data integration strategy leading to the identification of RIC8A as
a gene undergoing a classical double-hit genetic inactivation in a breast cancer cell line, as well as in
vivo evidence of loss of RIC8A expression in a subgroup of aggressive TP53 mutant breast cancers.
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Identification of genetic events that are involved in the
development of human cancer has been facilitated by the
availability of advanced genomic microarray platforms
[1]. However, often the mechanisms by which these
genetic events influence target genes in the chromosomal
regions affected and eventually on the tumourigenic proc-
ess, remain unknown. Altered genomic regions identified
by e.g. array-based comparative genomic hybridization
(aCGH), may contain hundreds of candidate genes mak-
ing the identification of specific disease-causing changes
challenging. We have recently applied nonsense-mediated
mRNA decay (NMD) microarray [2], and integrated data
from this technology with data from aCGH [3,4]. Tran-
scripts with nonsense mutations are selectively degraded
by the NMD pathway during translation [5]. Inhibition of
the NMD pathway can be exploited to detect changes in
the stability of transcripts carrying such truncating muta-
tions. As bi-allelic inactivation of tumour suppressor
genes often involves loss of the second copy of the
genomic region harbouring these genes, integrating data
from using NMD microarrays with whole genome CGH
microarray data may help in order to focus the search to
deleted chromosomal areas (Figure 1). Using integration
of unbiased genome-wide data from these two technolo-
gies, we describe here the identification of a putative target
gene, RIC8A, located in a frequently deleted region at
11p15 in breast cancer. RIC8A was flagged as a candidate
for undergoing NMD in the breast cancer cell line ZR-75-
1. Furthermore, we bioinformatically explored the in vivo
levels of expression of this gene in datasets from two pub-
lished breast cancer studies [6,7]. RIC8A interacts with
GDP-bound G-alpha protein [8], has been found to be
associated with mitotic spindle alignment in asymmetric
cell division in the fly [9], and includes a protein motif
that is involved in regulation of mitosis [10]. We therefore
hypothesized that this gene may play a role in breast can-
cer development or progression.
Methods
Cell culture and emetine treatment
We used six commonly studied breast cancer cell lines,
representing different types of breast cancer; MDA-MB-
468 (ER-, PR-, TP53 mutation), MDA-MB-231 (ER-, PR-,
TP53 mutation), ZR-75-1 (ER+, PR+), MCF7 (ER+, PR+),
BT-474 (ER+, PR+, TP53 mutation) and T-47D (ER+, PR+,
TP53 mutation) and three non-malignant cell lines;
HMECs (non-malignant human mammary epithelial
cells), IMR90 (normal lung fibroblasts) and WS1 (normal
skin fibroblasts). All cell lines were obtained from Ameri-
Overview of the microarray data integrationFigure 1
Overview of the microarray data integration. A)"DNA/RNA outlier plot" of cell line ZR-75-1. The x-axis indicates the 
DNA copy number ratio of all 54675 probe sets on the Affymetrix U133plus2.0 array. These ratios were calculated from Agi-
lent array CGH data for the same genes. The y-axis indicates the expression ratio of all probe sets compared to the median of 
other cell lines. Putative NMD hits are shown in red. RIC8A is both heterozygously deleted, underexpressed compared to the 
other cell lines and its expression was induced by emetine treatment. B)A schematic view of chromosome 11 in ZR-75-1, as 
well as the deleted region at 11p15.5. RIC8A is located ~200 kb from the p-telomere.Page 2 of 8
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with the distributor's instructions. Both malignant and
non-malignant cell lines were treated with the translation
inhibitor emetine dihydrochloride hydrate (Sigma-
Aldrich, St Louis, MO). For each cell line, parallel cell cul-
tures were grown in 175 cm2 flasks until 70–80% conflu-
ence. Half of the subconfluent cultures were treated with
100 μg ml-1 of emetine dihydrochloride hydrate while the
other half were left as untreated controls. Both emetine-
treated and untreated cells were incubated at 37°C for 10
h. After drug exposure, cells were trypsinated, cell pellets
snap-frozen and total RNA was extracted using RNeasy
mini kit (Qiagen, GmbH, Hilden Germany) as described
by the manufacturer. RNA quality was evaluated using an
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo
Alto, California, USA). Genomic DNA was extracted from
untreated cells using the NucleoSpin Tissue kit with the
protocol for cultured cells (Macherey-Nagel, Düren, Ger-
many).
NMD microarrays
We used Affymetrix Human Genome U133 plus 2.0 Gene-
Chip oligonucleotide arrays to compare emetine-treated
and untreated cells. 3 μg of total RNA per sample was pre-
pared according to the manufacturer's protocols. For
hybridization, fragmented cRNA (15 μg from each sam-
ple) was used. The arrays were stained with phycoeryth-
rin-streptavidin and the signal intensity was amplified by
treatment with a biotin-conjugated anti-streptavidin anti-
body, followed by a second staining using phycoerythrin-
streptavidin. Finally, the stained arrays were scanned
using the GeneChip Scanner 3000 (Affymetrix). Data
were analyzed using GeneChip Operating Software 1.1
(Affymetrix).
aCGH analysis
Array-based CGH was carried out using DNA from the
untreated breast cancer cell lines. Agilent Human Genome
CGH microarray 44 k was utilized according to the proto-
col provided by the manufacturer (Agilent Technologies,
Palo Alto, California, USA). Genomic DNA pooled from
healthy female donors was used as reference in all hybrid-
izations. Briefly, six micrograms of digested and purified
tumour and reference DNA was labelled with Cy5-dUTP
and Cy3-dUTP (Perkin-Elmer, Wellesley, Massachusetts,
USA), respectively, in a random priming reaction using
BioPrime DNA Labelling System (Invitrogen, Carlsbad,
California, USA). Labelled tumour and reference samples
were pooled and hybridized onto the arrays according to
the protocol. After hybridization arrays were washed and
scanned with a laser scanner (G2565 Scanner, Agilent
Technologies). Feature Extraction software version 7.5.1
(Agilent Technologies) was used to extract the signal
intensities. CGH Analytics software version 3.4.27 (Agi-
lent Technologies) was used for data visualization.
Microarray data analysis
Data from the Affymetrix gene expression arrays were nor-
malized using the dChip method [11]. Gene expression
and aCGH data were combined by calculating, for each
probe set, the median of all aCGH oligos located between
the start and end base pair positions of the gene the probe
set mapped to. Probe set to gene mappings were retrieved
from NetAffx (April 2005) and all base pair positions are
based on the May 2004 human genome build. The data
have been deposited in NCBIs Gene Expression Omnibus
(GEO, http://www.ncbi.nlm.nih.gov/projects/geo/) and
are accessible through GEO Series record GSE15477.
Selection and prioritization of genes from the NMD 
microarray data
The most promising candidate genes for harbouring trun-
cating mutations based on the NMD data in each breast
cancer cell line were selected using the following criteria:
I) the gene was induced by emetine at least 1.5 fold (log2
scale) in the cancer cell line and not in any of the other cell
lines. II) Expression in the clean (no emetine treatment)
sample was lower than in any of the clean samples from
all other cell lines. III) The gene was located in a hetero-
zygously deleted region. IV) Expression after emetine
treatment was over 50 units (to exclude genes expressed at
levels which are not measured reliably).
Patient cohorts
A previously described cohort of early stage breast cancer
(I/II) [7,12] was used for validation. From this, DNA from
127 tumours was used to sequence the RIC8A gene. Gene
expression data from 115 tumours of the same cohort
were used for in silico validation of expression levels and
38 of these were validated by qRT-PCR. Methylation anal-
ysis was performed on 86 tumours from a cohort of early
lesions of breast cancer, 27 pure DCIS, 27 pure invasive (<
15 mm) and 32 mixed lesions (invasive with in situ com-
ponent) [13] and in 75 DNA tumour samples from
patients with locally advanced breast cancer (T3/T4) [14].
Microarray data of RIC8A were further in silico validated in
251 primary breast tumours [6].
Mutation analysis
PCR primers with M13 tails were designed to amplify the
exons plus 50 bp of intronic sequence at both ends of each
exon (for primer sequences see Additional file 1). PCR
products were purified with PCR cleanup filter plates
(Millipore) and sequenced using M13 primers and
BigDye v.1.1 on a 3730 DNA analyzer (Applied Biosys-
tems).
cDNA synthesis and real-time PCR analysis
cDNA was generated in a total volume of 20 μl with 50 ng
total RNA using GeneAmp® Gold RNA PCR Core kit
(Applied Biosystems). Real-time PCR experiments werePage 3 of 8
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(Applied Biosystems) on an ABI Prism 7900 HT sequence
detector system (Applied Biosystems). The primers
included were designed to overlap exon-exon boundaries
to avoid genomic DNA contamination. Universal human
reference RNA (Stratagene) was used to generate standard
curves. Each sample was run in triplicate and the relative
gene expression levels were determined with the standard
curve method and normalized using PGK1 as reference
gene.
DNA methylation analysis by pyrosequencing
1 μg of DNA was bisulphite converted using the Meth-
ylEasy™ HT Kit for Centrifuge (Human Genetic Signatures,
North Ryde, Australia) according to the manufacturer's
instructions. Quantitative DNA methylation analysis of
the bisulphite treated DNA was performed by pyrose-
quencing [15]. 98 CpGs spanning 2 kb of genomic
sequence were quantitatively analyzed at single nucle-
otide resolution. The investigated regions comprised the
entire promoter region as well as other regions of the large
CpG island (nucleotides -943 to +1338 relative to the
transcription start site). Oligonucleotides for PCR ampli-
fication and pyrosequencing were synthesized by Biotez
(Buch, Germany) and sequences are given in Additional
file 2.
Statistics
Student's t-test and Mann-Whitney test were performed
using SPSS (version 15.0. SPSS Inc, Chicago, Illinois,
USA) for association with clinical parameters. In the
microarray datasets used for validation, samples with
RIC8A signal intensity < 650 were considered as low
expressed and RIC8A signal intensity > 950 as highly
expressed. With this range, about 15% of the tumours
showed low expression, a frequency similar to what was
observed in other published data sets [16,17].
Results
Identification of genes subject to NMD-degradation by 
microarray analysis
We measured levels of gene expression by microarrays
before and after pharmacological inhibition of the NMD-
pathway in order to identify candidate genes for mutation
screening in six breast cancer cell lines (MDA-MB-468,
MDA-MB-231, ZR-75-1, MCF7, BT-474 and T-47D). In
total, using our prioritization criteria (see Methods) for
the NMD microarray results, 51 candidate genes were
identified of which three were prioritized for analysis by
DNA sequencing to identify putative mutations (Addi-
tional file 3). The normalized NMD microarray ratios for
the three genes were 1) 1.89 for PGPEP1 (Entrez
GeneID:54858) in the BT-474 cell line compared to the
other five cell lines, 2) 5.16 for COL12A1 (Entrez
GeneID:1303) in ZR-75-1 cells compared to the other
lines, and 3) 1.5 for RIC8A (Entrez GeneID:60626) in ZR-
75-1 cells, also compared to the other five cell lines. The
three selected candidate genes were sequenced in all six
breast cancer cell lines. Sequence analysis of RIC8A con-
firmed a hemizygous nonsense mutation, GAG → TAG in
the last codon of exon 3 in the ZR-75-1 cell line, and not
in any of the other cell lines. Further, RIC8A, located at
11p15.5, was heterozygously deleted according to the
aCGH data and showed a low level of expression also in
non-treated ZR-75-1 cells compared to the other cell lines,
suggesting bi-allelic inactivation of the gene in these cells
(Figure 1A+B). We confirmed the differential expression
of RIC8A in the ZR-75-1 cell line compared to the other
cell lines by qRT-PCR (Figure 2). The remaining two can-
didate genes selected for sequencing displayed wild type
DNA sequences in all six breast cancer cell lines.
Sequencing of RIC8A in clinical breast cancer samples
To further determine the relevance of the mutation in clin-
ical specimens, we sequenced all ten exons of RIC8A in
127 tumour samples obtained from patients with early-
stage breast cancer. We could not find nonsense muta-
tions or other amino acid changing mutations in any of
these tumours. Notably, we have previously demon-
strated the ability to detect mutations in only 10–15% of
cells in a sample with this sequencing technology.
To evaluate if RIC8A could be silenced by CpG hyper-
methylation in the promoter regions, we pyrosequenced
98 CpGs spanning 1 kb upstream of the transcription start
site as well as the 3' end of the large CpG island down-
stream of the transcription start site in pre-invasive
(DCIS) (n = 27) and invasive tumours with DCIS compo-
nents (n = 32), in early invasive breast cancer (n = 27) as
well as a cohort of 75 locally advanced breast cancers. All
CpG positions upstream of the transcription start were
found to be unmethylated in all samples, while some
methylation was observed at CpGs downstream of the
transcription start as well as at the 3' end of the CpG island
where methylation levels reached 40–80%. However,
DNA from normal breast tissue samples displayed identi-
cal methylation patterns indicating that RIC8A is not a tar-
get for epigenetic silencing (data not shown).
Bioinformatics and qRT-PCR analysis of RIC8A in clinical 
breast cancer cohorts
To examine the importance of RIC8A as a target gene for
the frequent deletion in chromosome band 11p15 in
breast cancer, we analyzed the expression of RIC8A in pre-
viously published breast cancer microarray data sets. First,
a gene expression dataset consisting of 251 consecutively
collected breast cancers [6] displayed low RIC8A tran-
script levels in 15% of the tumours and a significant asso-
ciation was shown between low RIC8A gene expression
and ER-negativity (P < 0.001), PR-negativity (P < 0.003)Page 4 of 8
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smaller dataset of 115 early-stage breast tumours [7] dis-
played low RIC8A expression in 19% of the tumours and
showed borderline significant association between low
RIC8A gene expression and PR-negativity (P = 0.054) and
TP53 mutation (P = 0.071) (Figure 3B). Finally, qRT-PCR
analysis by TaqMan of 38 of these tumours validated that
there was an association between low RIC8A- expressing
tumours and the presence of TP53 mutations (Mann-
Whitney test: P = 0.006) (Figure 3C).
Discussion
We describe here an integrated genomic approach for the
genome-wide-screening for putative tumour suppressor
genes in cancer. Given the multitude of potential target
genes in frequently deleted regions of the cancer genome,
strategies to narrow down the candidates for detailed
study would lead to more efficient identification of cancer
genes. Here, we describe how a data integration approach
combining three microarray technologies (aCGH, gene
expression arrays and NMD microarrays) made it possible
to narrow the search for potential mutated genes to three
tumour suppressor candidates, one of which, RIC8A, was
confirmed to show a truncating mutation, deletion and
loss of expression in a breast cancer cell line. Furthermore,
while the clinical breast cancers had no clear pathogenetic
mutations, a subset of clinical breast cancers associated
with aggressive features showed low levels of RIC8A
expression indicating that inactivation of this gene may
play a role in the pathogenesis of a subset of breast can-
cers.
This represents the second example of NMD-based discov-
ery identifying a novel truncating mutation in cancer. Our
previous studies of prostate cancer cell lines identified
EPHB2 as a target for similar deletion-truncation events in
the DU-145 cells [3]. Therefore, it is clear that some, but
not all mutations are highlighted by the NMD-based strat-
egy, particularly in combination with the aCGH data.
Treatment with translation inhibitors, such as emetine,
extends the half-lives of numerous transcripts [18]. In
addition, nonsense-mediated mRNA decay (NMD) is
known to regulate a significant number of genes under
physiological conditions [19], as well as to prevent incor-
rectly spliced genes from being translated [20]. To avoid
selection of stress-response genes or those normally regu-
lated by NMD, we applied stringent filtering criteria to the
NMD microarray data from six breast cancer cell lines.
These included first, presence of the candidate gene in a
deleted region of the genome in that cell line, correspond-
ing with the two-hit Knudson hypothesis of tumour sup-
pressor gene inactivation, and second, a low relative
baseline mRNA expression. Using this integrated genomic
approach we limited the list of candidates for sequencing
to 51. The three top candidate genes with the clearest
increase in normalized NMD ratios were sequenced in all
cell lines. Of these, RIC8A showed a truncating mutation.
After discovery of a mutation in a cancer cell line, the
more challenging task is to ascertain the significance and
prevalence of such mutations in clinical samples. The key
question here is as to whether the mutation is critical to
the pathogenesis of cancer and common across a set of
cancers, or possibly a "passenger mutation" selected along
with a more important other mutation. Although muta-
tions in the coding region of RIC8A were not found in the
cohort of 127 early-stage breast cancers, we cannot rule
out that mutations might exist at a low frequency in more
advanced cases. Exhaustive pyrosequencing of the entire
RIC8A promoter region in early invasive breast cancers as
well as in pre-invasive tumours (DCIS) and locally
advanced (T3/T4) tumours excluded also promoter hyper-
methylation as a mechanism for RIC8A gene silencing.
Recent estimates of the prevalence of somatic mutations
in human cancers are highly variable both within and
between classes of cancer [21]. The emerging pattern is
that there are relatively few frequently mutated genes,
(most of these already known) and a very large number of
rare mutations, often highly varying from one case to
another [22]. Based on the lack of mutations identified in
clinical breast cancer samples as well as the lack of evi-
dence from cancer genome sequencing studies indicating
involvement of RIC8A [22,23], we postulated that RIC8A
Validation of RIC8A expression in cell lines by qRT-PCRFigure 2
Validation of RIC8A expression in cell lines by qRT-
PCR. Relative expression level of RIC8A measured by Taq-
Man qRT-PCR in treated vs. non-treated cell lines is shown 
with black and grey bars, respectively. Each sample was run 
in triplicate and the relative gene expression levels were 
determined with the standard curve method and normalized 
using PGK1 as reference gene.Page 5 of 8
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RIC8A expression levels associated with different molecular parametersFigure 3
RIC8A expression levels associated with different molecular parameters. A: Gene expression in the Miller et al. 2005 
data [6]: The 251 breast tumours separated based on ER, PR and TP53 status. TP53 mutated group includes all tumours with a 
signature of TP53 inactivation [6]. B: Gene expression in the Naume et al. 2007 data [7]: The 115 breast tumours separated 
based on ER, PR and TP53 status. C: RIC8A expression by TaqMan qRT-PCR. The 38 tumours separated based on TP53 muta-
tion status. Each square represents the expression level of RIC8A in one tumour. Red bars indicate group medians.
BMC Medical Genomics 2009, 2:26 http://www.biomedcentral.com/1755-8794/2/26inactivation could either be a rare genetic event in breast
cancer, or possibly, its inactivation in clinical samples
could take place more often through other mechanisms,
not involving direct truncating mutations or methylation.
RIC8A was originally found by genetic studies in C. elegans
and reported to act in vitro as a guanine nucleotide
exchange factor (GEF) for G protein alpha subunits [8].
Several studies have since reported that RIC8A is required
for G-protein signalling and is involved in centrosome
movements during early embryogenesis in C. elegans
[24,25]. In addition, RIC8A was discovered to be required
for proper asymmetric division of one-cell-stage in both
C. elegans embryos [26] and Drosophila [9]. However, the
physiological role of the mammalian homolog RIC8A in
G protein-coupled receptor signalling in intact cells is
largely unknown. Yet, a human mitotic phosphorylation
motif associated with protein localization to the mitotic
apparatus was recently identified in RIC8A, suggesting a
role for RIC8A in mitosis [10]. This point to the possibility
that RIC8A would play a role in cancer relevant pathways
and that its inactivation could be important to the patho-
genesis of the disease.
Bioinformatics analysis of microarray data from 251 con-
secutive breast cancers [6] showed that low RIC8A expres-
sion was significantly associated with hormone receptor
negativity (ER and PR) as well as presence of TP53 muta-
tions. A similar analysis of gene expression in 115
tumours from another cohort focussing on early breast
cancer indicated a similar, but statistically weaker trend
(Figure 3). The association between low RIC8A expression
and TP53 mutations was validated by the analysis using
qRT-PCR of 38 tumours from the early stage cohort [7].
Furthermore, a previously published analysis of 171 pri-
mary breast tumours showed that the chromosome 11p
telomeric region is lost at an approximate frequency of
15% [16]. The frequency is highest towards the distal part
of the chromosome, where RIC8A is located, and declines
towards the centromere. In the same tumours, genes in
this region, including RIC8A, were shown to be statisti-
cally significantly deleted and underexpressed when com-
bining copy number and gene expression data. Also, this
deletion was statistically significantly associated to both
recurrence and distant metastases in this patient cohort.
There was no significant association with any other clini-
cal parameter. Yet another study showed that 11p15.5-
p15.4 copy number loss in primary breast cancers was
associated with a higher incidence of recurrent disease in
tamoxifen-treated patients [17]. While RIC8A is located in
one of the most frequently deleted regions in breast cancer
[27], the deletion obviously involves a large number of
genes. We therefore evaluated whether the flanking genes
from RIC8A would show similar statistical associations
between low expression and ER/PR negativity and TP53
mutation, respectively. For example, this region harbours
the SIRT3 gene, which has been associated with cancer
[28,29] and whose expression showed correlation with
copy number loss together with RIC8A [16]. However, in
our analyses RIC8A showed the strongest association with
aggressiveness. Together with the presence of the truncat-
ing mutation, this suggests a specific importance of the
RIC8A gene in a subset of breast cancers.
Conclusion
We demonstrate here that integrating microarray data
from three different methods (aCGH, expression, non-
sense-mediated mRNA decay) facilitated the identifica-
tion of putative tumour suppressor genes undergoing bi-
allelic inactivation in cancer. Here, this strategy led to the
identification of RIC8A as a gene undergoing deletional
and mutational inactivation in a breast cancer cell line, as
well as in vivo evidence of loss of its expression in a sub-
group of aggressive breast cancers.
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